Tumor necrosis factor in blood plasm and morphofunctional parameters of the heart in patients with chronic heart failure complicating the course of ischemic heart disease. Changes in response to treatment


如何引用文章

全文:

详细

Aim. To examine the course of chronic cardiac failure (CCF), morphofunctional parameters of the heart in correlation with activity of cytokine system; to evaluate effectiveness, tolerance and safety of combined CCF treatment including a cardioselective fi-adrenoblocker bisoprolol in patients with CCF FC I-IV having a high plasm level of tumor necrosis factor a (TNF-a).
Material and methods. The concentration of TNF-a in plasm of 40patients with IHD complicated by CCF of FC I-IV and ejection fraction under 45% was measured at enzyme immunoassay. The treatment included combined therapy with diuretics, cardiac glycosides, peripheral vasodilators, ACE inhibitors, bisoprolol (group 1) or no bisoprolol (group II).
Results. CCF patients with TNF-a had a significally reduced IMT, more frequent episodes of CCF decompensation, longer CCF history, lower EF and threshold exercise intensity. In group I patients all these parameters improved.
Conclusion. CCF patients with elevated plasm levels of TNF-a showed a severe course of the disease, low IMT, abnormal myocardial contraction and exercise tolerance. The addition of bisoprolol to combined treatment of the above patients improves their clinical condition, morphological parameters of the heart and exercise tolerance.

参考

  1. Anker S. D.. Chua T. P., Ponicowski P. Hormonal changes and metabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-534.
  2. Anker S. D., Clark A. I., Teixeira M. M. et al. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am. J. Cardiol. 1999; 83: 612-615.
  3. Anker S. D., Swan J. W., Vollerrani M. et al. The influance of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur. Heart J. 1997; 18: 259-269.
  4. Katz A. M., Katz B. P. Diseases of heart in works of Hippocrates. Br. Heart J. 1962; 24: 257-264.
  5. Kleber F. X., Petersen S. The peripheral syndrome of heart failure: the overlooked aspects. Eur. Heart J. 1998; (suppl. L): L10-L14.
  6. Riley M., Elbom J. S., McKane W. R. et al. Resting energy expenditure in chronic cardiac failure. Clin. Sci. 1991; 80: 633- 639.
  7. Swan J. W., Anker S. D., Walton C. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J. Am. Coll. Cardiol. 1997; 30: 527-532.
  8. Cook S. A., Poole-Wilson P. A. Cardiac myocyte apoptosis. Eur. Heart J. 1999; 20: 1619-1629.
  9. Meldrum D. R. Tumour necrosis factor in the heart. Am. J. Physiol. 1998; 274: R577-R595.
  10. Levine В., Kalman K., Mayer L. et al. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N. Engl. J. Med. 1990: 323: 236-241.
  11. Murdoch D. R., McMurray J. J. V. Cardiac cachexia-lean and mean. Eur. Heart J. 20: 1609-1611.
  12. Progress in the treatment of heart failure: Materials of 8th International congress on cardiovascular pharmacotherapy. Amsterdam; 1999. 16.
  13. Thomas J. A., Marks В. Н. Plasma norepinephrine in congestive heart failure. Am. J. Cardiol. 1978; 41: 233-243.
  14. Swedbeig K., Hjalmarson A., Waagstein F. Beneficial effects of long term beta blockade in congestive cardiomyopathy. Br. Heart J. 1980; 44: 117-123.
  15. Ольбинская Л. И., Игнатенко С. Б. Современные представления о патогенезе и лечении хронической сердечной недостаточности. Клин. мед. 2000; 8: 22-27.
  16. Torre-Amione С., Kapadia S., Benedict С. et al. Proinflammatory cytokine levels in patient with depressed left ventricular ejection fraction. J. Am. Coll. Cardiol. 1996; 27: 1201-1206.
  17. Ольбинская Л. И., Лазебник Л. Б. Донатры оксида азота в кардиологии. М.; 1998.
  18. Rohb MacLellan W., Schneider M. D. Death by design. Circ. Res. 1997; 81: 137-144.
  19. Koseki Т., Inohara N., Cnen S. et al ARC, an inhibitor of apoptosis expressed in sceletal muscle and heart that interacts selectively with caspases. Proc. Natl. Acad. Sci. USA 1998; 95: 5156-5160.
  20. Yue T.-L., Wang C., Romanic A. et al. Stauresporine-induced Apoptosis in cardiomyocytes: A potential role for Caspase-3. J. Mol. Cell. Cardiol, 1998; 30: 495-507.
  21. Ponikowski P., Piepoli M., Chua T. P. et al. The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. Eur. Heart J. 1999; 20: 1667-1675.
  22. Mortana A., La Rovere M. Т., Pinna G. D. et al. Arterial baroreflex modulation on heart rate in chronic heart failure. Circulation 1997; 96: 3450-3458.
  23. Ponikowski P., Anker S. D., Chua T. P. et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ishemic or idiopathic dilated cardiomyopathy. Am J. Cardiol. 1997; 79: 1645-1650.
  24. Ponikowski P., Chua T. P., Piepoli M. et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation 1997; 96: 2586-2594.
  25. Sowton E., Hamer J. Hemodynamic changes after beta adrenergic blockade. Am. J. Cardiol. 1996; 18: 317-320.
  26. Olbinskaya L. I., Ignatenko S. N., Sisova Zh. M. Efficacy of bisoprolol, pl-selective adrenoblocker, in chronic heart failure patients with cardiac cachexia syndrome. Eur. Heart J. 2000; 21: 661.
  27. Waagstein F., Hjalmarson A. et al. Eggect of chronic betaadrenergic receptor blockage in congestive cardiomyopathy. Br. Heart J. 1975; 137: 1022-1036.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2003

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##